<DOC>
	<DOCNO>NCT00280631</DOCNO>
	<brief_summary>The purpose study determine safety efficacy TLK199 Tablets patient Myelodysplastic Syndrome ( MDS )</brief_summary>
	<brief_title>Study TLK199 Tablets Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>This Phase 1-2a study open label , dose‑ranging study TLK199 Tablets patient World Health Organization French‑American‑British classification type myelodysplastic syndrome ( MDS ) . In Phase 1 , safety , pharmacokinetics , hematologic response rate TLK199 Tablets evaluate . The Phase 1 dose‑ranging stage design determine maximum tolerate dose optimal biologic dose TLK199 Tablets . Evaluation pharmacokinetics TLK199 Tablets conduct . In Phase 1 , additional 12 patient undergo pharmacokinetic evaluation feed condition select Phase 2a dose . In Phase 2a , safety hematologic response modify International Working Group MDS response criterion study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Histologically confirm diagnosis MDS Documented significant cytopenia least 2 month Adequate liver kidney function Ineligible stem cell bone marrow transplantation At least 18 year age Discontinuation growth factor ( e.g. , GCSF ) within 3 week study entry Prior bone marrow transplant Failure recover prior surgery major surgery within 4 week study entry Pregnant lactate woman Other investigational drug within 14 day study entry Chemotherapy , radiotherapy immunotherapy within 14 day study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>